Abivax reports H1 2026 results; appoints new CMO and CTO
Abivax SA reported first-half 2026 results and named Chris Rabbat as CMO and Tim Kelly as CTO as it advances toward potential commercialization of obefazimod.
Abivax SA reported first-half 2026 results and named Chris Rabbat as CMO and Tim Kelly as CTO as it advances toward potential commercialization of obefazimod.